Piccin et al. (2017) analyzed the levels of circulating MPs in ET patients, reporting that in ET subjects on risk-adapted therapy, particularly acetylsalicylic acid alone or in combination with hydroxyurea, total MPs and PMPs, i.e., CD61(+) and CD36(+), were lower versus controls or anagrelide-treated ET patients (p < 0.001). This evidence concerns the gene CD36 and essential thrombocythemia.